Minerva Biotechnologies Announces FDA Acceptance of IND Application for huMNC2-CAR44 T cells to Treat Metastatic Breast Cancer
Alteogen Inc. gets IND approval for a clinical study in Korea for Eylea Biosimilar (ALT-L9)
HAMLET Pharma Appoints Issa PR to Launch First Major Clinical Trials for a New Cancer Killing Molecule
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0022, a Novel MET/CSF1R/SRC Inhibitor
LY09004 Approved for Clinical Trials in China, Luye Pharma Steps-up Global R&D Investment in Biopharma Medicines
- Advertisement -